BPC-157 has dozens of animal studies. The human evidence fits on one page
A 2025 systematic review found 35 preclinical studies and a single clinical one. Here is what the few human reports did, and did not, show.
At a glance
- Systematic review
- 36 studies included: 35 preclinical, 1 clinical (HSS Journal, 2025)
- Largest human report
- A look back at the records of 16 people given knee injections, with no comparison group
- Safety study
- Two adults given infusions over two days (2025); tested blood markers did not change
- Clinical safety data
- None found by the 2025 review
- Status
- Not approved anywhere; banned in sport by WADA
The research, explained
BPC-157 is one of the most talked-about recovery peptides. Online it is described as a healing aid for tendons, muscles and the gut. In the research literature, almost all of that reputation comes from rats and mice.
A 2025 systematic review for sports medicine searched three medical databases for every study of its mechanism, effects on muscles and joints, metabolism and safety. Of 544 articles, 36 met the criteria: 35 preclinical studies and one clinical study. In animal models, BPC-157 improved healing measures in muscle, tendon, ligament and bone injuries.
The clinical study was a 2021 chart review from a Florida clinic. Staff phoned 16 people who had received knee injections and asked them to rate their pain. Of the 12 who received BPC-157 alone, 11 reported significant improvement. There was no placebo group, no standard measurement tool, and follow-up time varied, so the result cannot separate the peptide from natural recovery or expectation.
A 2025 pilot study looked at safety when BPC-157 was given into a vein. It included two adults, both of whom had received it before. Blood tests of the heart, liver, kidneys, thyroid and blood sugar did not change over the two-day study, and no side effects were reported. Two people over two days cannot establish safety.
A 2026 primer for orthopaedic surgeons reached a similar view: the benefits are “largely unvalidated in human trials”, and the knee report has “significant methodological flaws and a lack of controls”.
BPC-157 is also on the FDA’s agenda. Advisers discussed it in July 2026 as a possible compounding ingredient for ulcerative colitis (read our report). Laboratory research material is listed in the research shop; it is not a medicine, and it is not the material used in these reports.
What does this mean?
The animal research gives scientists good reasons to run proper trials. Until randomized human trials report, claims about healing in people rest on very thin evidence.
What don’t we know yet?
Whether BPC-157 helps people heal, which side effects it causes and what long-term use does are unanswered. The 2025 review adds that harm is possible from unregulated manufacturing and contamination.
Watch and learn
Videos discussing the compounds in this article, plus background on the biology or the research methods. Each card explains its connection; recordings may predate the findings described here.
Dr Brad Stanfield
Should you take BPC-157 peptides?
What the research on BPC-157 actually contains, study by study.
Brad Stanfield, MBChB, general practitioner
Discusses the compound
Discusses BPC-157, TB-500 or its clinical context. Read the original studies linked here for the exact formulation, population and outcomes.
Pain Specialists Australia
BPC-157 for pain: what the evidence actually says
Two pain specialists weigh the evidence and the risks of BPC-157, TB-500, ARA-290, MOTS-c and GHK-Cu, including contamination of products sold online.
Dr Nick Christelis and Dr Bradley Lewinsohn, specialist pain medicine physicians (FFPMANZCA)
Discusses the compound
Two specialist pain physicians review the evidence for BPC-157 (from 16:08), TB-500 (24:04), ARA-290 (4:54), MOTS-c (25:51) and GHK-Cu (24:56), and the risks of unregulated products.
Khan Academy
Phagocytes and innate immunity
How part of the immune system responds to threats and contributes to inflammation.
Immune-system biology education
Related biology
Background on immune cells and inflammation for understanding BPC-157, TB-500. It does not demonstrate benefits of this compound or formulation.
Sources and references
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic ReviewVasireddi et al. · HSS Journal · 2025
- Intra-Articular Injection of BPC 157 for Multiple Types of Knee PainLee & Padgett · Alternative Therapies in Health and Medicine · 2021
- Safety of Intravenous Infusion of BPC157 in Humans: A Pilot StudyLee et al. · Alternative Therapies in Health and Medicine · 2025
- Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine PhysiciansMayfield et al. · American Journal of Sports Medicine · 2026
- July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory CommitteeUS Food and Drug Administration
VETUD Learn explains published research in plain language. It is general information, not medical advice. Talk to a doctor before starting, stopping or changing any treatment.
In the research shop
Check the catalog for related laboratory research materials. These products are separate from the approved medicines and clinical trial formulations discussed here.
Checking regional availability…
